At the same time that it closed its first significant financing round - a $36 million Series A - Lux Biosciences Inc. gained worldwide rights to a late-stage immunosuppressant drug from Isotechnika Inc. to develop for ophthalmic diseases. (BioWorld Today)
Shares of Pharmacopeia Drug Discovery Inc. jumped 26.3 percent after the company signed a drug discovery deal with Cephalon Inc. that includes a $15 million up-front fee and the potential for double-digit royalties. (BioWorld Today)
Shares of Pharmacopeia Drug Discovery Inc. jumped 26.3 percent after the company signed a drug discovery deal with Cephalon Inc. that includes a $15 million up-front fee and the potential for double-digit royalties. (BioWorld Today)
Adventrx Pharmaceuticals Inc. and the FDA have agreed on a special protocol assessment for a Phase III trial of its chemotherapy enhancing drug, CoFactor, expected to start this quarter. (BioWorld Today)
Adventrx Pharmaceuticals Inc. and the FDA have agreed on a special protocol assessment for a Phase III trial of its chemotherapy enhancing drug, CoFactor, expected to start this quarter. (BioWorld Today)
